Hologic, Inc. (NASDAQ:HOLX) Receives $87.00 Average Target Price from Brokerages

Shares of Hologic, Inc. (NASDAQ:HOLX) have received a consensus recommendation of “Hold” from the nine research firms that are currently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $87.00.

HOLX has been the subject of several recent research reports. StockNews.com downgraded shares of Hologic from a “buy” rating to a “hold” rating in a report on Friday, March 8th. William Blair reiterated an “outperform” rating on shares of Hologic in a report on Friday, February 2nd. Evercore ISI boosted their price target on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price objective on shares of Hologic in a research note on Wednesday, April 10th. Finally, Raymond James boosted their target price on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd.

Insider Buying and Selling at Hologic

In other news, CFO Karleen Marie Oberton sold 14,940 shares of the firm’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $75.00, for a total value of $1,120,500.00. Following the transaction, the chief financial officer now owns 103,916 shares of the company’s stock, valued at approximately $7,793,700. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CFO Karleen Marie Oberton sold 14,940 shares of the company’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $75.00, for a total value of $1,120,500.00. Following the completion of the transaction, the chief financial officer now directly owns 103,916 shares in the company, valued at $7,793,700. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the transaction, the director now owns 48,611 shares in the company, valued at approximately $3,670,130.50. The disclosure for this sale can be found here. Insiders have sold a total of 32,846 shares of company stock worth $2,473,443 in the last quarter. 1.75% of the stock is owned by insiders.

Institutional Investors Weigh In On Hologic

Hedge funds and other institutional investors have recently modified their holdings of the stock. Nordea Investment Management AB boosted its holdings in Hologic by 4.5% in the third quarter. Nordea Investment Management AB now owns 1,616,999 shares of the medical equipment provider’s stock worth $113,077,000 after purchasing an additional 69,494 shares during the period. Pathstone Family Office LLC grew its holdings in shares of Hologic by 96.0% during the third quarter. Pathstone Family Office LLC now owns 9,272 shares of the medical equipment provider’s stock valued at $643,000 after purchasing an additional 4,542 shares during the last quarter. Ontario Teachers Pension Plan Board raised its position in shares of Hologic by 186.7% during the 3rd quarter. Ontario Teachers Pension Plan Board now owns 38,404 shares of the medical equipment provider’s stock worth $2,665,000 after purchasing an additional 25,010 shares during the period. HB Wealth Management LLC boosted its position in Hologic by 18.1% during the 3rd quarter. HB Wealth Management LLC now owns 5,774 shares of the medical equipment provider’s stock valued at $401,000 after purchasing an additional 884 shares during the period. Finally, McGuire Investment Group LLC grew its position in shares of Hologic by 0.3% during the fourth quarter. McGuire Investment Group LLC now owns 139,161 shares of the medical equipment provider’s stock worth $9,943,000 after acquiring an additional 366 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Up 0.2 %

Shares of NASDAQ HOLX opened at $75.10 on Tuesday. The company has a current ratio of 3.89, a quick ratio of 3.18 and a debt-to-equity ratio of 0.55. The stock has a market cap of $17.63 billion, a P/E ratio of 35.59, a PEG ratio of 2.54 and a beta of 1.00. The business’s fifty day simple moving average is $75.71 and its 200-day simple moving average is $72.50. Hologic has a 12-month low of $64.02 and a 12-month high of $87.88.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.03. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The company’s revenue for the quarter was down 5.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.07 EPS. As a group, equities analysts predict that Hologic will post 4.02 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.